Table 1.
Characteristics of study population
| Characteristic | Median (IQR) or N (%) at V2 (n=435) | Median (IQR) or N (%) at V4 (n=321) | Median (IQR) or N (%) at V6 (n=142) | Median (IQR) or N (%) All Person-Visits (n=898) |
|---|---|---|---|---|
| LVMI | 33.6 (27.7–39.4) | 31.5 (26.7–36.5) | 28.6 (24.0–33.5) | 32.0 (26.6–37.8) |
| LVH | 68 (16) | 43 (13) | 16 (11) | 127 (14) |
| Age at ECHO (yr) | 12 (8–15) | 13 (10–17) | 14 (11–18) | 13 (9–16) |
| Female sexa | 176 (40) | 125 (39) | 53 (37) | 189 (40) |
| African-American racea | 90 (21) | 58 (18) | 29 (20) | 103 (22) |
| Weight percentileb | 44.1 (19.6–77.1) | 48.4 (20.7–76.8) | 50.9 (18.8–78.3) | 46.9 (19.6–77.2) |
| Height percentileb | 24.7 (8.1–52.7) | 27.1 (8.8–50.8) | 29.1 (11.8–52.6) | 26.0 (8.8–52.5) |
| BMI percentileb | 61.1 (35.4–85.5) | 61.3 (32.7–87.2) | 61.9 (31.9–85.9) | 61.3 (34.3–86.2) |
| BMI>95th (obese)b | 68 (16) | 45 (14) | 17 (12) | 130 (14) |
| Low birth weighta | 79 (19) | 57 (19) | 22 (16) | 84 (18) |
| Preterm birth<36 wka | 54 (13) | 39 (13) | 13 (9) | 59 (13) |
| Duration of CKD | 7.4 (4.0–11.2) | 9.4 (6.3–12.7) | 10.9 (8.5–14.2) | 8.6 (5.6–12.5) |
| Glomerular CKDa | 87 (20) | 52 (16) | 21 (15) | 97 (20) |
| Iohexol GFR | 43.8 (32.7–56.9) | 45.6 (32.3–61.4) | 41.1 (30.2–55.2) | 43.8 (32.1–58.0) |
| SBP z scoreb,c | 0.4 (−0.3–1.0) | 0.0 (−0.6–0.7) | 0.1 (−0.5–0.7) | 0.2 (−0.4–0.8) |
| DBP z scoreb,c | 0.5 (−0.1–1.1) | 0.2 (−0.3–0.8) | 0.4 (−0.4–0.9) | 0.4 (−0.2–0.9) |
| Antihypertensive medications | 283 (65) | 210 (65) | 98 (69) | 591 (66) |
| ACEI/ARB | 237 (54) | 177 (55) | 86 (61) | 86 (61) |
| Calcium channel blocker | 63 (14) | 45 (14) | 25 (18) | 133 (15) |
| Other | 13 (3) | 9 (3) | 2 (1) | 24 (3) |
| ≥2 medications | 30 (7) | 21 (7) | 15 (11) | 66 (7) |
| Hypoalbuminemia | 5 (1) | 0 (0.0) | 0 (0.0) | 5 (1) |
| Nephrotic proteinuriad | 53 (13) | 49 (16) | 25 (19) | 127 (15) |
| Hemoglobin | 12.6 (11.7–13.6) | 12.7 (11.6–13.8) | 12.6 (11.4–13.8) | 12.7 (11.6–13.7) |
| Anemia | 132 (31) | 100 (31) | 50 (37) | 50 (37) |
| wrCRPe | 0.3 (0.1–1.8) | 0.2 (0.0–1.3) | 0.3 (0.2–1.9) | 0.3 (0.1–1.6) |
| Albumin-corrected calcium | 9.4 (9.1–9.6) | 9.2 (9.0–9.5) | 9.1 (8.8–9.3) | 9.3 (9.0–9.5) |
| Phosphate | 4.7 (4.2–5.2) | 4.5 (4.0–5.1) | 4.4 (3.9–5.0) | 4.6 (4.0–5.1) |
| Calcium × phosphate | 44.0 (39.1–48.8) | 42.0 (37.2–47.0) | 39.6 (35.1–45.0) | 42.6 (37.7–47.7) |
IQR, interquartile range; BMI, body mass index; wrCRP, wide range C-reactive protein.
a
All person-visits statistic is participant-based (n=478).
b
Based on mean of values from two visits.
c
Adjusted for age, sex, and height.
d
Protein to creatinine ratio>2.
e
wrCRP measured at V1b, V3 and V5.